As of November 14, 2026, Ventyx Biosciences, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 4, 2026 (Form 8-K, March 4, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Ventyx Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Ventyx Biosciences, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-04. Every row below is cited to the filing it comes from, and this page adds each new change as Ventyx Biosciences, Inc. files it.
Also on the record for Ventyx Biosciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 15, 2026 | Stake report, Schedule 13G/A, by TANG CAPITAL MANAGEMENT, LLC | — | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G/A, by Affinity Asset Advisors, LLC | — | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G/A, by Glazer Capital, LLC | — | 5%+ stakes | Source |
| March 5, 2026 | Stake report, Schedule 13D/A, by Subramaniam Somu | — | 5%+ stakes | Source |
| March 4, 2026 | Acquired by Eli Lilly and Company | $1.20B | Acquisition | Source |
| February 19, 2026 | Stake report, Schedule 13G, by Glazer Capital, LLC | 6.23% of the class | 5%+ stakes | Source |
| February 6, 2026 | Stake report, Schedule 13G/A, by Morgan Stanley | 0.3% of the class | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13G, by Morgan Stanley | 6% of the class | 5%+ stakes | Source |
| January 29, 2026 | Stake report, Schedule 13G/A, by Affinity Asset Advisors, LLC | 9% of the class | 5%+ stakes | Source |
| January 9, 2026 | Stake report, Schedule 13D/A, by Raju Mohan | 6% of the class | 5%+ stakes | Source |
| January 9, 2026 | Stake report, Schedule 13D/A, by Subramaniam Somu | 5.8% of the class | 5%+ stakes | Source |
| November 26, 2025 | Stake report, Schedule 13D, by Raju Mohan | 6% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Ventyx Biosciences, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Ventyx Biosciences, Inc. and the records around it.
Ventyx Biosciences, Inc. elsewhere on the record
- 5%+ stake filings May 2026
- Acquisition Mar 2026
Companies that share a holder
- Affinity Asset Advisors, LLC also filed stake reports on 16 other companies: Amanat Acquisition Corp. (Nov 2026), Equillium Inc. (Nov 2026), Forte Biosciences, Inc. (Nov 2026)
- TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 33 other companies: EyePoint, Inc. (Oct 2026), Skye Bioscience, Inc. (Oct 2026), Nano Dimension Ltd. (Aug 2026)
- Point72 Asset Management, L.P. also filed stake reports on 90 other companies: Immunocore Holdings plc (Nov 2026), Target Hospitality Corp. (Nov 2026), E.W. SCRIPPS Co (Oct 2026)
Watch Ventyx Biosciences, Inc.
Get an email when Ventyx Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Ventyx Biosciences, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Ventyx Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ventyx Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 16 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-03-04 | Reported | not named in the filing | 8-K, 2026-03-04 |
New leaders reset buying decisions — get the Full Report on Ventyx Biosciences, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Ventyx Biosciences, Inc., with the record behind each one.
Find candidates like senior executive at Ventyx Biosciences, Inc.Every change, in the filing's words
Reported
In accordance with the terms of the Merger Agreement, at the Effective Time, Onaiza Cadoret-Manier, Sheila Gujrathi, Allison Hulme, Raju Mohan, Somu Subramaniam, and William White, each of whom was a director of the Company as of immediately prior to the Effective Time, resigned and ceased to be a director of the Company and a member of any committee of the Company's Board of Directors.
- In accordance with the terms of the Merger Agreement, at the Effective Time, Christopher Anderson, Jonathan R. Haug and Sherry D. Davis, the directors of Merger Sub immediately prior to the Effective Time, became directors of the Company.
- In accordance with the terms of the Merger Agreement, at the Effective Time, Raju Mohan, Mark Forman, Roy Gonzales, Matthew Moore and John Nuss resigned from their positions as officers of the Company.
- In accordance with the terms of the Merger Agreement, at the Effective Time, the officers of Merger Sub immediately prior to the Effective Time, Jonathan R. Haug as President, Steffanie Lim-Ho as Treasurer, Christopher Anderson as Secretary, Jonathan Groff as Assistant Secretary and Katie Lodato as Assistant Treasurer, became the officers of the Company.
Tools for this story
Each opens in a new tab, filled in for Ventyx Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
